Am I a Candidate for Syfovre or Izervay?
Syfovre and Izervay at a Glance
You may be a candidate if three things are true. A retina specialist has found geographic atrophy (clinical: patches of the central retina that have thinned and stopped working) on retinal imaging. The atrophy comes from age-related macular degeneration. And your eye has no active infection or inflammation in it right now. Both drugs are labeled for geographic atrophy caused by age-related macular degeneration, and neither is labeled for any other cause of retinal thinning.12
Medical eligibility is the easy half. The harder half is a judgment call you make with your doctor about whether a modest, slow benefit is worth years of injections.
Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) are complement inhibitors. They quiet one arm of the immune system that appears to drive the loss of retinal cells in geographic atrophy.3 The goal is to slow how fast the atrophy spreads across your macula, so the retina you still use keeps working longer. In the pegcetacoplan trials, atrophy in treated eyes grew roughly one sixth to one fifth more slowly than in untreated eyes over two years.4 Both drugs reached the United States market in 2023, which means their long-term record is still short.5
This is the part that changes most people's decision. Neither drug has been shown to improve eyesight or bring back vision that is already gone.3 In the two-year pegcetacoplan trials, there were no differences between treated and untreated eyes in the key secondary vision measures, including the standard eye-chart score.4 So the honest framing is this: the imaging changes, and the hope is the eye chart follows later. That hope is reasonable, and it is not yet demonstrated.
Geographic Atrophy and Why These Drugs Exist
Geographic atrophy is the advanced form of the 'dry' type of macular degeneration. Areas of the macula, the small central part of the retina that handles sharp detail, gradually thin out and lose function, which makes reading, driving, and recognizing faces harder.6 It usually spreads slowly, over years rather than weeks. Many people first notice trouble in dim light, or a blurred spot just off center that creeps toward the middle.
It is uncommon, and it belongs to later life, because it grows out of age-related macular degeneration. In an analysis of Medicare Advantage enrollees published in the Journal of Managed Care and Specialty Pharmacy, about 5 of every 1,000 members had geographic atrophy in a given year.7 Because it is uncommon, most general eye clinics see it rarely, and the drug decision usually belongs with a retina specialist.
Complement is a set of blood proteins that helps the immune system clear debris. In macular degeneration, that system appears to stay switched on and damage healthy retinal cells along with the debris. Syfovre and Izervay both act on that pathway, which is why they are grouped together even though they are separate drugs.3 Blocking the pathway slows the damage, but it does not rebuild retina that has already been lost, which is the ceiling on what any current drug in this class can offer.
Who Is Considered a Good Candidate
The decision starts with imaging, not symptoms. Retina specialists confirm and measure geographic atrophy using optical coherence tomography, fundus photography, and fundus autofluorescence, which lights up the borders of the atrophy so it can be measured over time.6 Two scans months apart show how fast your atrophy is moving. That growth rate, plus how much healthy macula you still have, shapes the recommendation more than any single visit.
A patch that has barely moved in a year is a different problem from one that is expanding quickly toward your center of vision. One retina specialist quoted by the American Academy of Ophthalmology reserves these drugs for patients who show fast progression over six to twelve months, on the reasoning that slow progressors may never lose central vision to atrophy at all.5 That is one clinician's approach, not a formal rule, and practice varies. Still, it captures the common logic: treat where the threat is real and near.
The people studied were not everyone with macular degeneration. The pegcetacoplan trials enrolled adults aged 60 and older with geographic atrophy from macular degeneration.4 The GATHER2 trial of avacincaptad pegol enrolled adults aged 50 and older whose atrophy did not yet involve the exact center point of the macula, with eye-chart vision between 20/25 and 20/320.8 If your eye looks nothing like those, the evidence is thinner for you. Say so in the consult.
Geographic atrophy often affects both eyes, though rarely at the same pace. Both labels describe dosing into each affected eye, so treating two eyes means two injections at each visit.12 Some people start with the worse eye and watch the other. Others prioritize the better-seeing eye, since that is the eye doing the daily work. Ask your surgeon which they suggest.
Who Should Wait, and Who Should Skip Treatment
Some situations close the door for now. Both drugs are contraindicated in people with an infection in or around the eye, and in people with active inflammation inside the eye.12 Syfovre is additionally contraindicated in anyone with a known hypersensitivity to pegcetacoplan or to the other ingredients in it.1 These are usually pauses, not permanent bars. The infection gets managed, the eye quiets down, and the conversation restarts.
Declining is a legitimate choice here, not a failure to comply. In that same Academy article, one retina specialist reported that fewer than 5 of every 100 of his patients with geographic atrophy chose to go ahead once burden, risk, and benefit had been discussed plainly.5 People decline for practical reasons. Vision in the eye may already be very limited. Monthly travel may be too hard. Or the risk of bringing on the wet form may outweigh a slower line on a scan.
Wet macular degeneration is a different problem, driven by leaky new blood vessels. The most common treatment for it is anti-VEGF injections, which help stop the bleeding and leaking at the back of the eye.9 Complement inhibitors are not a treatment for that leakage. If an eye develops the wet form during treatment, your retina specialist will address that first, then decide with you whether to continue the atrophy drug.
How Syfovre and Izervay Are Given
Both are given as an injection into the vitreous gel inside the eye, in the office, by a retina specialist. Their schedules differ, and that is one of the real distinctions between them.
| Drug | Dose per affected eye | How often |
|---|---|---|
| Syfovre (pegcetacoplan) | 15 mg in 0.1 mL | Once every 25 to 60 days |
| Izervay (avacincaptad pegol) | 2 mg in 0.1 mL | Once monthly, about every 28 days |
Those doses and intervals come from each drug's prescribing information.12
The visit is short. Your eye is numbed with drops or a gel, the surface is cleaned, and a small clip holds your lids open. The injection takes a few seconds, and most people feel pressure rather than pain. Grittiness, a red patch on the white of the eye, and new floaters for a day or two are common and settle on their own. Arrange a ride, since vision is blurry afterward.
There is no course that finishes. Both drugs are given on an ongoing basis, once a month or every other month, for as long as you and your doctor decide to continue.3 Ask at the outset what would make your team stop: a certain amount of vision lost, a side effect, atrophy that reaches the center anyway, or simply your own decision that the trade is no longer worth it.
Side Effects and Risks Worth Weighing
Most side effects are ordinary consequences of an injection into the eye. The Izervay label lists bleeding on the white of the eye, a rise in eye pressure, blurred vision, and eye pain among its more common reactions.2 The Syfovre label lists eye discomfort, floaters, and bleeding on the white of the eye.1 These are uncomfortable rather than dangerous, and generally clear within days.
Two rare problems carry real weight. The first is endophthalmitis, an infection inside the eye, which both labels carry a warning about because it is a risk of any injection into the eye.12 The second is specific to Syfovre. Its label warns that retinal vasculitis or retinal vascular occlusion, usually alongside inflammation inside the eye, has been reported, that cases can happen after the very first dose, and that they can result in severe vision loss.1 The American Society of Retina Specialists described at least 14 affected eyes in 13 patients after a first pegcetacoplan injection.5 What protects the eye is speed. Report any change in vision the same day, so the drug can be stopped and the eye managed early.1
This is the most likely serious side effect, and it deserves plain numbers. In the Syfovre trials, by month 24 the wet form of macular degeneration developed in about 12 of every 100 eyes injected monthly and about 7 of every 100 injected every other month, against about 3 of every 100 in the untreated comparison group.1 The Izervay label reports the wet form in roughly 7 to 12 of every 100 treated eyes depending on the time point.2 In GATHER2 at one year the figures were about 7 of every 100 treated eyes against about 4 of every 100 untreated eyes.8 There is an established treatment for the wet form, which is why treated eyes are watched closely at every visit.9
What Realistic Results Look Like
Both drug programs measured the area of atrophy on retinal imaging, not the eye chart. In the OAKS trial, atrophy grew about 22 percent more slowly with monthly pegcetacoplan over 24 months, and about 18 percent more slowly with every-other-month dosing; in DERBY the figures were about 19 percent and 16 percent.4 In GATHER2, atrophy grew about 14 percent more slowly with monthly avacincaptad pegol over 12 months.8 Those are differences in a growth rate, a smaller thing than it first sounds.
A slower-growing patch should, in theory, eventually mean more vision preserved. So far the trials have not captured that. The pegcetacoplan trials reported no differences in key secondary vision measures at 24 months.4 A later analysis of those same trials found a directionally slower decline in eye-chart vision and quality of life where the atrophy sat further from the center of the macula, but the differences did not reach statistical significance.10 Two years may simply be too short for a slow disease. That is a real possibility, not evidence of benefit.
Treatment decisions are not all-or-nothing. The Academy's advice for macular degeneration includes not smoking, staying active, and using low-vision help: magnifiers, better task lighting, and a referral to a low-vision specialist to keep reading and stay independent.6 Many practices also ask patients to check each eye separately on an Amsler grid at home, so new distortion gets reported between visits.
Cost, Coverage, and Time
Both drugs are bought by the practice and given in the office rather than picked up at a pharmacy. Each carries its own billing code for the office setting, so the drug and the injection run through your medical coverage rather than a pharmacy plan.11 For most people aged 65 and older that means Medicare plus whatever secondary policy they carry. Ask the practice for a written benefits check before the first injection, and ask about each drug maker's patient assistance program.
Count the visits before you commit. Monthly injections in both eyes mean roughly twelve trips a year, each with dilation, waiting, and a driver. Add the imaging visits between. For people who live far from a retina practice, or who depend on a working family member for rides, that burden often decides the question.
Warning Signs to Call Your Doctor About the Same Day
After any injection in the eye, a few changes need same-day attention. Do not wait a week to see if they settle.
- Severe eye pain, or pain that is getting worse.
- Sudden vision loss, or vision that dims over hours.
- Redness that keeps building, light sensitivity, or discharge.
- A shower of new floaters, or flashing lights.
The Syfovre label tells patients to report any change in vision without delay.1 The American Academy of Ophthalmology says to call your ophthalmologist right away for eye pain, light sensitivity, or any change in vision after these injections.3 Most of these calls turn out to be ordinary soreness. Call anyway. The rare causes are manageable when they are caught in hours.
Straight lines that look wavy, a new dark or empty spot near the center, or a sudden drop in reading vision without pain are all reasons to call the retina practice within a day or two. These can signal the wet form starting, and anti-VEGF injections are the usual treatment for it.9 Ordinary soreness for a day, or one new floater that fades, does not need an urgent call.
Expect scans at regular intervals, so your team can see whether the atrophy border is still moving and whether the wet form has appeared. Bring a list of what has changed in daily function since the last visit: reading, night driving, faces. Those details often say more about whether to continue than the millimeter measurements do.
Questions Patients Ask Before Starting
No. Neither drug has been shown to improve eyesight or restore vision that is already gone.3 They aim to slow how fast the atrophy spreads on retinal scans. If someone offers you either drug as a way to read again or drive again, that is a promise the evidence does not support, and it is worth a second opinion from a retina specialist.
No head-to-head trial has compared them, so any ranking is an inference across studies with different designs. The practical differences are schedule and safety profile: Syfovre allows every-other-month dosing, while Izervay is labeled monthly.12 Syfovre also carries a labeled warning about retinal vasculitis and vascular occlusion that the Izervay label does not.12 Your retina specialist weighs those against your eye and your schedule.
Yes. This is elective treatment for a slow disease, and stopping is not an emergency. Tell your doctor you are thinking about stopping, rather than simply missing appointments, so your monitoring scans continue and the wet form is still spotted if it appears. Many people try a few months and then decide. Ask what your doctor expects your atrophy to do once treatment ends.
The injection itself takes seconds and is done after numbing drops or gel, so most people report pressure rather than sharp pain. Soreness, grittiness, and a red patch on the white of the eye for a day or two are normal. What is not normal is pain that increases over the following days, which is one of the same-day warning signs listed above.
Higher on treatment than off it. In the pegcetacoplan trials, by month 24 the wet form appeared in about 12 of every 100 eyes injected monthly, against about 3 of every 100 untreated eyes.1 It is also treatable with anti-VEGF injections,9 which is why your team will scan you regularly and ask you to report new distortion promptly.
Age alone does not disqualify anyone. The more useful questions are how fast your atrophy is moving, how much working macula you still have, and whether you can get to appointments. When an eye already has very limited vision, some retina specialists question whether the benefit shown so far is worth the burden and the risk.5 That reasoning is legitimate to raise yourself.
More Questions About Living With Treatment
Usually, though the details are plan-specific. These are office-administered drugs with their own billing codes, so they run through medical coverage rather than a pharmacy plan.11 Approval still depends on documented geographic atrophy and your plan's rules, and your share depends on any secondary policy. Ask for a written benefits check before starting, not after the first injection.
Neither label restricts use by where the atrophy sits.12 But the GATHER2 trial excluded eyes whose atrophy already involved the exact center point of the macula, so the evidence for avacincaptad pegol comes from eyes that had not reached that stage.8 If your center is already involved, ask your retina specialist what benefit they realistically expect for your eye.
Yes, and this is a fast-moving area. Several new approaches are being studied in clinical trials, and none of them is available outside a study today. Asking your retina specialist whether a trial is enrolling near you is reasonable at any point, including instead of starting one of the approved drugs.
- How fast has my atrophy grown between my last two scans?
- How much of my macula is still working, and where is the atrophy heading?
- Which drug do you recommend for my eye, and what makes it the better fit?
- What would make you tell me to stop treatment?
- What is my expected share of the cost, in writing?
- Is there a clinical trial I should consider instead?
- Who do I call after hours if my eye hurts or my vision drops?
- FDA prescribing information (US product labeling), revised 7/2025, via DailyMed (2025). SYFOVRE (pegcetacoplan injection) prescribing information, sections 2 (Dosage and Administration), 4 (Contraindications), 5.2 (Retinal Vasculitis and/or Retinal Vascular Occlusion), 5.3 (Neovascular AMD) and 6 (Adverse Reactions).
- FDA prescribing information (US product labeling), revised 2/2026, via DailyMed (2026). IZERVAY (avacincaptad pegol intravitreal solution) prescribing information, sections 2.1 (Recommended Dosage), 4 (Contraindications), 5 (Warnings and Precautions) and 6 (Adverse Reactions).
- American Academy of Ophthalmology EyeSmart, written by Reena Mukamal, reviewed by Rahul N. Khurana, MD (2025). What to Know About Syfovre and Izervay for Geographic Atrophy.
- Heier JS, Lad EM, Holz FG, et al. The Lancet 2023;402(10411):1434-1448 (2023). Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
- EyeNet Magazine, American Academy of Ophthalmology, May 2024 (2024). New Geographic Atrophy Drugs: The Good, the Bad, and the Unknown.
- American Academy of Ophthalmology EyeSmart patient education. Geographic Atrophy: Causes, Symptoms, Treatment.
- Journal of Managed Care & Specialty Pharmacy 2025;31(1):88-96 (2025). Annual prevalence of geographic atrophy and wet age-related macular degeneration among Medicare Advantage enrollees in a US health plan.
- Khanani AM, Patel SS, Staurenghi G, et al. The Lancet 2023;402(10411):1449-1458 (2023). Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
- National Eye Institute, National Institutes of Health, last updated December 2024 (2024). Treatments for Wet AMD (Advanced Neovascular AMD).
- Chiang A, Davis M, Stevens W, et al. American Journal of Ophthalmology 2025 (2025). Visual Acuity and Quality of Life Outcomes With Pegcetacoplan Treatment: A Post Hoc Analysis From the OAKS and DERBY Trials.
- Shah AR, Woodke J. EyeNet Magazine, American Academy of Ophthalmology, November 2023 (2023). Geographic Atrophy: How to Get Paid for New Treatments.